| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 634 | 2020 |
| Ipilimumab for patients with relapse after allogeneic transplantation MS Davids, HT Kim, P Bachireddy, C Costello, R Liguori, A Savell, ... New England Journal of Medicine 375 (2), 143-153, 2016 | 581 | 2016 |
| Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline J Mikhael, N Ismaila, MC Cheung, C Costello, MV Dhodapkar, S Kumar, ... Journal of Clinical Oncology 37 (14), 1228-1263, 2019 | 274 | 2019 |
| Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 15 (2), 230-269, 2017 | 224 | 2017 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 194 | 2020 |
| NCCN guidelines insights: multiple myeloma, version 3.2018 SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018 | 154 | 2018 |
| NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines SK Kumar, NS Callander, J Hillengass, M Liedtke, M Baljevic, ... Journal of the National Comprehensive Cancer Network 17 (10), 1154-1165, 2019 | 153 | 2019 |
| NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines NS Callander, M Baljevic, K Adekola, LD Anderson, E Campagnaro, ... Journal of the National Comprehensive Cancer Network 20 (1), 8-19, 2022 | 128 | 2022 |
| Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma E Lazzari, PK Mondala, ND Santos, AC Miller, G Pineda, Q Jiang, H Leu, ... Nature communications 8 (1), 1922, 2017 | 102 | 2017 |
| Efficacy and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) T Gregory, AD Cohen, CL Costello, SA Ali, JG Berdeja, EM Ostertag, ... Blood 132, 1012, 2018 | 89 | 2018 |
| NCCN guidelines insights: multiple myeloma, version 3.2016 KC Anderson, M Alsina, D Atanackovic, JS Biermann, JC Chandler, ... Journal of the National Comprehensive Cancer Network 14 (4), 389-400, 2016 | 78 | 2016 |
| Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life E Terpos, J Mikhael, R Hajek, A Chari, S Zweegman, HC Lee, MV Mateos, ... Blood cancer journal 11 (2), 40, 2021 | 75 | 2021 |
| Multiple myeloma, version 2.2016 KC Anderson, M Alsina, D Atanackovic, JS Biermann, JC Chandler, ... Journal of the National Comprehensive Cancer Network 13 (11), 1398-1435, 2015 | 75 | 2015 |
| Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM)(PRIME) with novel therapeutic strategies CL Costello, AD Cohen, KK Patel, SS Ali, JG Berdeja, N Shah, S Ganguly, ... Blood 136, 29-30, 2020 | 72 | 2020 |
| A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation MS Davids, HT Kim, C Costello, AF Herrera, FL Locke, RO Maegawa, ... Blood, The Journal of the American Society of Hematology 135 (24), 2182-2191, 2020 | 72 | 2020 |
| Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from … M Sebag, NS Raje, NJ Bahlis, C Costello, B Dholaria, M Solh, MY Levy, ... Blood 138, 895, 2021 | 51 | 2021 |
| Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed … PM Voorhees, JL Kaufman, JP Laubach, DW Sborov, B Reeves, ... Blood 134, 691, 2019 | 50 | 2019 |
| Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression S Banerjee, T Wei, J Wang, JJ Lee, HL Gutierrez, O Chapman, SE Wiley, ... Proceedings of the National Academy of Sciences 116 (49), 24881-24891, 2019 | 49 | 2019 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of … JL Kaufman, JP Laubach, D Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 136, 45-46, 2020 | 46 | 2020 |
| Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM)(PRIME) CL Costello, TK Gregory, SA Ali, JG Berdeja, KK Patel, ND Shah, ... Blood 134, 3184, 2019 | 46 | 2019 |
